Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis

Neuropsychopharmacology

Volumn 31, Issue 2, 2006, Pages 431-441

  Gouzoulis Mayfrank, Euphrosyne ^a,b   Heekeren, Karsten ^a,b   Neukirch, Anna ^a,b   Stoll, Martina ^b   Stock, Carsten ^b   Daumann, Joerg ^a   Obradovic, Maja ^c   Kovar, Karl Artur ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Dimethyltryptamine; Experimental psychosis; Inhibition of Return (IOR); NDMA antagonist; Orienting of attention; S ketamine

Indexed keywords

KETAMINE; LYSERGIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N DIMETHYLTRYPTAMINE; SEROTONIN; SEROTONIN 2 AGONIST;

ADULT; ARTICLE; ATTENTION; CONTROLLED STUDY; DISEASE MODEL; DOSE CALCULATION; DOSE RESPONSE; DOWN REGULATION; DRUG INHIBITION; DRUG MEGADOSE; FACILITATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; ORIENTING RESPONSE; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; REACTION TIME; SAMPLE SIZE; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SPATIAL ORIENTATION;

ADULT; ATTENTION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INHIBITION (PSYCHOLOGY); KETAMINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; N,N-DIMETHYLTRYPTAMINE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 30944463238     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300882     Document Type: Article

References (62)

1. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH (1998). The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31S: 104-109.
2. Addington J, Addington D (1998). Visual attention and symptoms in schizophrenia: a 1-year follow-up. Schizophrenia Res 34: 95-99.
3. American Psychiatric Association (APA) (1994). DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Inc.: Washington, DC.
4. Andreasen NC (1984a). The scale for the assessment of negative symptoms (SANS). Department of Psychiatry, University of Iowa, Iowa City, Copyright by Andreasen NC, 1984.
5. Andreasen NC (1984b). The scale for the assessment of positive symptoms (SAPS). Department of Psychiatry, University of Iowa, Iowa City, Copyright by Andreasen NC, 1984.
6. Andreasen NC, Paradiso S, O'Leary DS (1998). 'Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical- cerebellar circuitry? Schizophrenia Bull 24: 203-218.
7. Arolt V, Teichert HM, Steege D, Lencer R, Heide W (1998). Distinguishing schizophrenic patients from healthy controls by quantitative measurement of eye movement parameters. Biol Psychiatry 44: 448-458.
8. Braff DL, Grillon C, Geyer MA (1992). Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49: 206-215.
9. Carpenter WT (1999). The schizophrenia ketamine challenge study debate. Biol Psychiatry 46: 1081-1091.
10. Carter CS, Robertson LC, Chaderjian MR, Celaya LJ, Nordahl TE (1992). Attentional asymmetry in schizophrenia: controlled and automatic processes. Biol Psychiatry 31: 909-918.
11. Carter CS, Robertson LC, Chaderjian MR, O'Shora-Celaya L, Nordahl TE (1994). Attentional asymmetry in schizophrenia: the role of illness subtype and symptomatology. Progr Neuropsychopharmacol Biol Psychiatry 18: 661-683.
12. D'Souza DC, Berman RM, Krystal JH, Charney DS (1999). Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry 46: 1060-1080.
13. Fecteau JH, Bell AH, Munoz DP (2004). Neural correlates of the automatic and goal-driven biases in orienting spatial attention. J Neurophysiology 92: 1728-1737.
14. Fuentes LJ, Boucart M, Alvarez R, Vivas AB, Zimmerman MA (1999). Inhibitory processing in visuospatial attention in healthy adults and schizophrenic patients. Schizophrenia Res 40: 75-80.
15. Fuentes LJ, Santiago E (1999). Spatial and semantic inhibitory processing in schizophrenia. Neuropsychology 13: 259-270.
16. Gold JM, Randolph C, Coppola R, Carpenter CJ, Goldberg TE, Weinberger DR (1992). Visual orienting in schizophrenia. Schizophrenia Res 7: 203-209.
17. Gouzoulis-Mayfrank E, Arnold S, Heekeren K (2005a). Deficient inhibition of return in schizophrenia - further evidence from an independent sample. Prog Neuropsychopharmacol Biol Psychiatry, in press, corrected proof, available online 12 July 2005.
18. Gouzoulis-Mayfrank E, Heekeren K, Timmerbeil A, Stoll M, Stock C, Obradovic M et al (2005b). Psychological effects of S-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry, in press.
19. Gouzoulis-Mayfrank E, Heekeren K, Voss T, Moerth D, Thelen B, Meincke U (2004). Blunted inhibion of return (IOR) - a trait marker of schizophrenia? Prog Neuro-Psychopharmacol Biol Psychiatry 28: 389-396.
20. Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H (1998a). History, rationale and potential of experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 31(S2): 63-68.
21. Gouzoulis-Mayfrank E, Schneider F, Spitzer M, Thelen B, Sass H (1998b). Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry 31(S2): 114-118.
22. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M et al (1999a). Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20: 565-581.
23. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Hermle L et al (1999b). Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 142: 41-50.
24. Gouzoulis-Mayfrank E, Thelen B, Maier S, Habermeyer E, Kovar K-A, Sass H et al (2002). Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45: 205-212.
25. Holzman PS (1985). Eye movement dysfunctions and psychosis. Int Rev Neurobiol 27: 179-205.
26. Huey ED, Wexler BE (1994). Abnormalities in rapid, automatic aspects of attention in schizophrenia: blunted inhibition of return. Schizophrenia Res 14: 57-63.
27. Hulshoff Pol HE, Schnack HG, Mandl RC, Cahn W, Collins DL, Evans AC et al (2004). Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage 21: 27-35.
28. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
29. Karper LP, Freeman G, Grillon C, Morgan III CA, Charney DS, Krystal JH (1996). Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. J Neuropsych Clin Neurosci 8: 60-66.
30. Klein RM (2000). Inhibition of return. Trends Cogn Sci 4: 138-147.
31. Klein RM, Dick B (2002). Temporal dynamics of reflexive attention shifts: a dual-stream rapid serial visual presentation exploration. Psychol Sci 13: 176-179.
32. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
33. Larrison-Faucher A, Briand KA, Sereno AB (2002). Delayed onset of inhibition of return in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 26: 505-512.
34. Lepsien J, Pollmann S (2002). Covert reorienting and inhibition of return: an event-related fMRI study. J Cogn Neurosci 14: 127-144.
35. Liotti M, Dazzi S, Umilta C (1993). Deficits of the automatic orienting of attention in schizophrenic patients. J Psychiatr Res 27: 119-130.
36. Maruff P, Danckert J, Pantelis C, Currie J (1998). Saccadic and attentional abnormalities in patients with schizophrenia. Psychol Med 28: 1091-1100.
37. Maruff P, Hay D, Malone V, Currie J (1995). Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Neuropsychologia 33: 1205-1223.
38. Mayer AR, Dorflinger JM, Rao SM, Seidenberg M (2004a). Neural networks underlying endogenous and exogenous visual-spatial orienting. Neuroimage 23: 534-541.
39. Mayer AR, Seidenberg M, Dorflinger JM, Rao SM (2004b). An event-related fMRI study of exogenous orienting: supporting evidence for the cortical basis of inhibition of return? J Cogn Neurosci 16: 1262-1271.
40. Meyer-Lindenberg A, Poline JB, Kohn PD, Holt JL, Egan MF, Weinberger DR et al (2001). Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry 158: 1809-1817.
41. Nestor PG, Faux SF, McCarley RW, Penhune V, Shenton ME, Pollak S et al (1992). Attentional cues in chronic schizophrenia: abnormal disengagement of attention. J Abnormal Psychol 101: 682-689.
42. Oie M, Rund BR, Sundet K (1998). Covert visual attention in patients with early-onset schizophrenia. Schizophrenia Res 34: 195-205.
43. Øye N, Hustveit O, Moberg ER, Pausen O, Skoglund LA (1991). The chiral forms of ketamine as probes for NMDA receptor function in humans. In: Kameyama T, Nabeshima T, Domino ES (eds). NMDA Receptor Related Agents: Biochemistry, Pharmacology and Behavior. NPP Books: Ann Arbor. pp 381-389.
44. Øye N, Paulsen O, Maurset A (1992). Effects of ketamine on sensory perception: evidence for a roel of N-methyl-D-aspartate receptors. J Pharmacol Exp Therap 260: 1209-1213.
45. Posner MI, Cohen Y (1984). Components of visual orienting. In: Bouma H, Bouwhuis DG (eds). Attention and Performance. Control of Language Processing. Lawrence Erlbaum Associates Publishers: London. pp 531-556.
46. Posner MI, Early TS, Reiman E, Pardo PJ, Dhawan M (1988). Asymmetries in hemispheric control of attention in schizophrenia. Arch Gen Psychiatry 45: 814-821.
47. Posner MI, Rafal R, Choate LS, Vaughan J (1985). Inhibition of Return: neural basis and function. Cogn Neuropsychology 2: 211-228.
48. Potkin SG, Swanson JM, Urbaneck M, Carreon D, Bravo G (1989). Lateralized deficits in covert shifts of visual attention in chronic and never-medicated schizophrenics compared to normal controls. Schizophrenia Res 2: 95.
49. Ragland JD, Gur RC, Valdez J, Turetsky BI, Elliott M, Kohler C et al (2004). Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia. Am J Psychiatry 161: 1004-1015.
50. Rosen AC, Rao SM, Caffarra P, Scaglioni A, Bobholz JA, Woodley SJ et al (1999). Neural basis of endogenous and exogenous spatial orienting. A functional MRI study. J Cogn Neurosci 11: 135-152.
51. Sapir A, Henik A, Dobrusin M, Hochman EY (2001). Attentional asymmetry in schizophrenia: disengagement and inhibition of return deficits. Neuropsychology 15: 361-370.
52. Sapir A, Soroker N, Berger A, Henik A (1999). Inhibition of return in spatial attention: direct evidence for collicular generation. Nat Neurosci 2: 1053-1054.
53. Schlosser R, Gesierich T, Kaufmann B, Vucurevic G, Hunsche S, Gawehn J et al (2003). Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. Neuroimage 19: 751-763.
54. Sereno AB, Holzman PS (1995). Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psychiatry 37: 394-401.
55. Snyder SH (1988). Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology 1: 197-199.
56. Strauss ME, Alphs L, Boekamp J (1992). Disengagement of attention in chronic schizophrenia. Psychiatry Res 43: 87-92.
57. Strauss ME, Novakovic T, Tien AY, Bylsma F, Pearlson GD (1991). Disengagement of attention in schizophrenia. Schizophrenia Res 37: 139-146.
58. Taylor TL, Klein RM (1998). On the causes and effects of inhibition of return. Psychon Bull Rev 5: 625-643.
59. Vollenweider FX, Antonini A, Leenders KL, Oye I, Hell D, Angst J (1997). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25-38.
60. Weinberger DR, Berman KF, Zee RF (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114-124.
61. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825-844.
62. Wigal SB, Swanson JM, Potkin SG (1997). Lateralized attentional deficits in drug-free and medicated schizophrenic patients. Neuropsychologia 35: 1519-1525.